Product Description
The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. Celprogen is utilizing its stem cell plateform with synthetic viral peptides for production of their vaccine against SARS-CoV-2 virus. In their pre-clinical study the vaccine shows great potential. Celprogen in the process of submitting IND for theCOVID-19 Vaccine 32020. The vaccine is producing immunity and has safety and efficieny data. Celprogen is looking for Pharma and private partnership in their clinical trials of this vaccine. the storage conditions of this vaccine is -20C, and it requires two doses 2 weeks apart, in the limited testing of the vaccine no major side effects were observed.
